Navigation Links
New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation
Date:12/7/2008

"Having clear results from a robust Phase II study among atrial fibrillation patients gives us confidence in evaluating the doses selected for our Phase III clinical trial," said Francis Plat, M.D., vice president, clinical development at Daiichi Sankyo Pharma Development. "We are hopeful that DU-176b may one day provide the community with a safe and convenient treatment for the prevention of stroke in patients with non-valvular atrial fibrillation."

About the DU-176b Phase II Safety Study

A total of 1,146 patients with atrial fibrillation with a CHADS2 index >/= 2 were enrolled in the study. Patients were randomly assigned to receive either one of the four fixed dose regimens of DU-176b (30mg/N=235 or 60mg/N=234 administered once daily; 30mg/N=244 or 60mg/N=180 administered twice daily), or warfarin (N=250) dose-adjusted locally to a target International Normalized Ratio (INR) of 2.0-3.0 for 12 weeks. The INR was determined weekly for four weeks and every two weeks thereafter. Investigators, sponsors and study subjects were blinded to the DU-176b dose; however, those taking warfarin were aware they were randomized to the warfarin arm.

The primary endpoints of the study were the incidence of bleeding events (major and clinically relevant non-major) and elevated liver enzymes and/or bilirubin. Secondary endpoints included major adverse cardiovascular events, stroke, systemic embolism, acute myocardial infarction, hospitalizations due to cardiovascular conditions or cardiovascular death.

The incidence of major and clinically relevant non-major bleeding events was significantly higher with the 30 mg and 60 mg twice-daily DU-176b regimens (7.8 percent, p = 0.029 and 10.6 percent, p = 0.002 respectively) than it was in patients given warfarin (3.2 percent). In contrast, the incidence of major and clinically relevant non-major bleeding events with the 30 mg and 60 mg once-dai
'/>"/>

SOURCE Daiichi Sankyo Company, Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Strategic Health Services, Inc. (SHS), a leading provider of ... agreement with QualCare, Inc., a leading provider of health plans ... marketplace.  This agreement will further QualCare,s population health management ... brings to its clients in New Jersey ... QualCare plans cover more than 800,000 member lives, with ...
(Date:12/17/2014)... December 17, 2014 , ... than a hub of information concerning the biopharmaceutical Group,s national ... A further addition to the recently launched institutional website that ... now been enriched by a new chapter in the fascinating ... A richly detailed and panoramic hub on the world of ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 17, 2014 ... and Integrated Clinical Trial Services, LLC (ICTS), two ... clinical trials announce that they have formed a ... (i-CTMS). i-CTMS will provide a broad range of ... and medical device companies. i-CTMS will ...
Breaking Medicine Technology:Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3
... IDM Pharma, Inc.,(Nasdaq: IDMI ) today ... for Medicinal Products for Human Use (CHMP) and ... 25th, following the,CHMP,s September meeting where CHMP considered ... for the,treatment of patients with non-metastatic, resectable osteosarcoma, ...
... Preventing Possibly Life-Threatening,Condition During Air Travel, ALEXANDRIA, ... (APTA) supports the recent "Call to Action" by,Acting ... reduce the number of,cases of deep vein thrombosis ... According to Susan Scherer, PT, PhD, associate professor ...
Cached Medicine Technology:IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP) 2IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP) 3IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP) 4IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP) 5APTA Supports Surgeon General's 'Call to Action' to Prevent Deep Vein Thrombosis and Pulmonary Embolism 2APTA Supports Surgeon General's 'Call to Action' to Prevent Deep Vein Thrombosis and Pulmonary Embolism 3
(Date:12/15/2014)... CITY, NV (PRWEB) December 15, 2014 ... powerhouse company, JM Ocean Avenue. JM Ocean Avenue ... of the Veretekk online automated marketing system. JM ... the June 2014 merger of Ocean Avenue and JM ... more than $2 Billion per year company. , “After ...
(Date:12/15/2014)... 15, 2014 OutMarket , a ... “ Social Media Cheat Sheets ,” a guide that ... drives results on the top ten social media networks. ... helps drive awareness, engagement, and customer service. It can ... make an impact on new networks and weather constantly ...
(Date:12/15/2014)... 2014 The increase in prevalence of disabling ... main factors which is contributing to the growth in the ... and treatment of hearing loss and balance disorders are known ... - microphone, speaker and amplifier. The global market is expected ... during the period from 2014 to 2019. Some of the ...
(Date:12/15/2014)... 2014 At the leading, long-established event ... and Focus Autism will welcome scientists ... on the effects of toxins to children’s health, as ... , Luminaries such as Dr. Lucija Tomljenovic and ... esteemed, credentialed colleagues of the United States to present ...
(Date:12/15/2014)... Metal drilling machines have a ... score indicates that neither buyers nor suppliers have a ... been raising the price of metal drilling machines during ... demand,” according to IBISWorld business research analyst, Jeffrey Cohen. ... the past three years, high price driver volatility has ...
Breaking Medicine News(10 mins):Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3Health News:Metal Drilling Machines Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Metal Drilling Machines Procurement Category Market Research Report Now Available from IBISWorld 3
... ... Asks What’s Next for Doctors under New Healthcare Reform Bill, , ... Dallas, TX (Vocus) April 19, 2010 – The recent ... ’ ( Brown Books ) addresses how the health care system has been hostage for ...
... ... ... 18, 2010 -- This weekend, more than 30,000 attendees at the International Cannabis & ... to the nation’s first retail branded, complete medical marijuana product line. , , ,YAK ...
... to help with care, researchers say , SUNDAY, April 18 ... ill older people in the United States live alone, a ... to take care of their parents and relatives, a new ... significantly help many patients with chronic illness manage their health ...
... ... North East Alabama, has successfully completed deployment of CellTrak workflow automation and visit compliance ... HR payroll. , ... Schaumburg, IL (PRWEB) April 18, 2010 -- ABC Hospice, Inc, a premier hospice provider ...
... ... Washington, hits the big time , ... Oak Harbor, WA (PRWEB) April 19, 2010 -- In the highly-competitive natural skincare industry, ... Tacia, Oak Harbor resident and owner of Bella Vé Natural Skin Care, has recently launched ...
... faster times as the goal, while females hope to ... -- Women run marathons to feel good while men run ... suggests. , The research included 507 female and 399 male ... questionnaire designed to reveal the participants, motivation for taking part ...
Cached Medicine News:Health News:Recent Book Moves Beyond Defensive Medicine, Tackles Entitlement Reform 2Health News:Recent Book Moves Beyond Defensive Medicine, Tackles Entitlement Reform 3Health News:First Retail Branded Edible Medical Marijuana Product Line Introduced at San Francisco Trade Show 2Health News:First Retail Branded Edible Medical Marijuana Product Line Introduced at San Francisco Trade Show 3Health News:First Retail Branded Edible Medical Marijuana Product Line Introduced at San Francisco Trade Show 4Health News:1 in 4 Chronically Ill Elderly Lives Alone 2Health News:CellTrak Increases Employee Productivity and Efficiencies at ABC Hospice, Inc. 2Health News:CellTrak Increases Employee Productivity and Efficiencies at ABC Hospice, Inc. 3Health News:Hollywood Eco-Celebrity Rachelle Carson-Begley Gives Skincare Company Bella V Rave Reviews 2Health News:Hollywood Eco-Celebrity Rachelle Carson-Begley Gives Skincare Company Bella V Rave Reviews 3Health News:Hollywood Eco-Celebrity Rachelle Carson-Begley Gives Skincare Company Bella V Rave Reviews 4Health News:Are Male Marathoners More Competitive Than Women? 2
...
...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
Medicine Products: